{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:31:06Z","timestamp":1777883466969,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Sage Open Chronic Disease"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hepatitis B virus (HBV) infection is a leading cause of chronic liver disease and cancer globally, with perinatal transmission representing the predominant route of new infections in high-burden countries such as Nigeria. Despite significant prevalence, screening, diagnosis, and timely intervention for HBV among pregnant women remain suboptimal in Nigeria, contributing to ongoing morbidity and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This analysis assessed the impact of interventions to reduce perinatal HBV transmission in five pilot health facilities in Delta State, Nigeria. It evaluated HBV and HCV prevalence among pregnant women, timing of antenatal care (ANC) booking, linkage to care for HBV-positive women, and HepB birth dose (HepB-BD) vaccination coverage and timeliness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>The project design was a prospective implementation research which involved a cohort of pregnant women registered for ANC in the five pilot healthcare facilities strategically located across the three senatorial districts of Delta State, Nigeria. These facilities were all high-volume public facilities located and were carefully chosen to ensure representation across different regions of Delta State, providing a diverse perspective on the project\u2019s implementation and impact. The selected facilities provide secondary and tertiary care services.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      All pregnant women at five health facilities were screened at their first ANC visit for HBV and HCV using rapid testing. HBV-positive women were linked to care and initiated on tenofovir disoproxil fumarate (TDF) prophylaxis. The proportion of newborns receiving timely HepB-BD vaccination (within 24\u2009h of birth) was measured pre- and post-intervention. Statistical analysis was performed using paired\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      -tests and Chi-squared.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 2844 pregnant women were screened for HBV and HCV. The pooled prevalence of HBV infection among the study population was found to be 1.86% (95% CI: 1.35%\u20132.37%), six times higher than HCV (0.3%). A Chi-squared test for homogeneity was conducted to determine if the proportion of HBV-reactive individuals varied significantly across the five facilities. The test revealed a statistically significant difference in HBV prevalence across facilities (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200911.49,\n                      <jats:italic toggle=\"yes\">df<\/jats:italic>\n                      \u2009=\u20094,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.021). Most women (53.4%) booked ANC in the second trimester. Prior to intervention, the probability of administering the HepB vaccine to any child, whether newborn or older infants, on any day of the week, including weekends, was 40% because vaccination was not conducted daily in any of the pilot facilities. Post-intervention, this rose to 100% as all pilot facilities adopted daily vaccination practice. In comparison with the previous study of 5.8%, HepB-BD timely uptake within 24\u2009h, post-intervention, was 100% across all pilot facilities.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Project StopHepB interventions significantly improved early identification, linkage to care, and timely HepB-BD vaccination, effectively closing gaps in HBV prevention of perinatal transmission. These findings support the scale-up of similar interventions to advance HBV elimination goals across other facilities in the state, in Nigeria, and to prevent new HBV infections in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/27558428251400452","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:24:06Z","timestamp":1770107046000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Insights from strengthening perinatal hepatitis b prevention in healthcare facilities in Delta State, Nigeria: A prospective, pilot implementation intervention"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3961-3780","authenticated-orcid":false,"given":"Prince Ochuko","family":"Okinedo","sequence":"first","affiliation":[{"name":"Hepatitis Advocacy Foundation (HAF), Delta State, Asaba, Delta State, Nigeria"},{"name":"State Secretariat Clinic, Ministry of Health, Asaba, Delta State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-2105","authenticated-orcid":false,"given":"Catherine","family":"Freeland","sequence":"additional","affiliation":[{"name":"Hepatitis B Foundation (HBF), Doylestown, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6313-6031","authenticated-orcid":false,"given":"Ehimario U.","family":"Igumbor","sequence":"additional","affiliation":[{"name":"Centre for Infectious Disease Research, Nigerian Institute of Medical Research (NIMR), Lagos, Nigeria"},{"name":"School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel Okwuchukwu","family":"Ilikannu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Federal Medical Centre, Asaba, Delta State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funso Joshua","family":"Eniojukan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Niger Delta University, Wilberforce Island, Amassoma, Bayelsa State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0451-2635","authenticated-orcid":false,"given":"Ngozi Roy","family":"Maduka","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Central Hospital, Agbor, Delta State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregsonil Ogheneruemu","family":"Idibofu","sequence":"additional","affiliation":[{"name":"Hepatitis Advocacy Foundation (HAF), Delta State, Asaba, Delta State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Peter-Enyi","sequence":"additional","affiliation":[{"name":"Department of Public Health, Delta State Ministry of Health, Asaba, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Igweh","sequence":"additional","affiliation":[{"name":"Department of Public Health, Delta State Ministry of Health, Asaba, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafe","family":"Akokotu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services, Central Hospital, Agbor, Delta State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabastine","family":"Edokpayi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Central Hospital, Agbor, Delta State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Abifade","sequence":"additional","affiliation":[{"name":"Hepatitis Advocacy Foundation (HAF), Delta State, Asaba, Delta State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Igah","sequence":"additional","affiliation":[{"name":"Department of Public Health, Delta State Ministry of Health, Asaba, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ossai Abaniwa","family":"Theresa","sequence":"additional","affiliation":[{"name":"Department of Nursing Services, General Hospital, Ozoro, Delta State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki-Famous","family":"Betty","sequence":"additional","affiliation":[{"name":"Department of Laboratory Services, General Hospital, Ozoro and Central Hospital, Sapele, Delta State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Idegbesor","sequence":"additional","affiliation":[{"name":"Department of Laboratory Services, Central Hospital, Warri, Delta State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ubiri","family":"Obaherhekre","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services, Central Hospital, Sapele, Delta State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idanesi O","family":"Stella","sequence":"additional","affiliation":[{"name":"Department of Nursing Services, Central Hospital, Warri, Delta State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelechi","family":"Okorie","sequence":"additional","affiliation":[{"name":"Department of Laboratory Services, Asaba Specialist Hospital, Asaba, Delta State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyem Vivian","family":"Wamari","sequence":"additional","affiliation":[{"name":"Department of Nursing Services, Central Hospital, Agbor, Delta State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Tetsola","sequence":"additional","affiliation":[{"name":"Department of Public Health, Delta State Ministry of Health, Asaba, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva Switzerland: World Health Organization. https:\/\/www.who.int\/publications\/i\/item\/9789240091672 (2024 accessed 28 May 2025)."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22898"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30161-3"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.5334\/aogh.3226"},{"key":"e_1_3_3_6_2","unstructured":"World Health Organization. Meeting of the strategic advisory group of experts on immunization April 2017: conclusions and recommendations. Wkly Epidemiol Rec 2017; 92: 301\u2013320 https:\/\/www.who.int\/publications\/i\/item\/WER9222"},{"key":"e_1_3_3_7_2","unstructured":"World Health Organization. Global health sector strategies on respectively HIV viral hepatitis and sexually transmitted infections for the period 2022\u20132030. World Health Organization https:\/\/apps.who.int\/iris\/handle\/10665\/360348 (2022 accessed 20 May 2025)."},{"key":"e_1_3_3_8_2","unstructured":"Centers for Disease Control and Prevention. Partnering to increase hepatitis B birth dose vaccination in Africa. CDC Global Immunization https:\/\/www.cdc.gov\/global-immunization\/stories\/hepatitis-b-birth-dose-vaccination-in-africa.html (accessed 6 June 2025)."},{"key":"e_1_3_3_9_2","unstructured":"Gavi. Why a birth dose of hepatitis B vaccine could be life-changing https:\/\/www.gavi.org\/vaccineswork\/why-birth-dose-hepatitis-b-vaccine-could-be-life-changing (accessed 16 April 2025)."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13795"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.51412\/psnnjp.2025.10"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.1993.0102"},{"key":"e_1_3_3_13_2","unstructured":"World Health Organization. A Guide for Introducing and Strengthening Hepatitis B Birth Dose Vaccination. World Health Organization https:\/\/apps.who.int\/iris\/handle\/10665\/208278 (2015 accessed 18 February 2024)."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0001332"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0001052"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.09.056"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126461"},{"key":"e_1_3_3_18_2","unstructured":"Nigeria Federal Ministry of Health and Social Welfare; Nigeria National Population Commission; ICF. Nigeria Demographic and Health Survey 2023\u201324: Key Indicators Report. NPC and ICF https:\/\/dhsproject.com\/publications\/publication-PR157-Preliminary-Reports-Key-Indicators-Reports.cfm (2024 accessed 10 September 2024)."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30056-6"},{"key":"e_1_3_3_20_2","unstructured":"International Agency for Research on Cancer. Nigeria fact sheet. GCO 2021. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/566-nigeria-fact-sheets.pdf (2019 accessed 4 May 2021)."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30279-6"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0259218"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.10.110"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4557-0090-5.00025-2"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.29245\/2578-3009\/2018\/si.1104"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00304-1"}],"container-title":["Sage Open Chronic Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/27558428251400452","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/27558428251400452","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/27558428251400452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:46:47Z","timestamp":1777600007000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/27558428251400452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":25,"alternative-id":["10.1177\/27558428251400452"],"URL":"https:\/\/doi.org\/10.1177\/27558428251400452","relation":{},"ISSN":["2755-8428","2978-1558"],"issn-type":[{"value":"2755-8428","type":"print"},{"value":"2978-1558","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"27558428251400452"}}